About: Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.64 (-0.36%)
ESLANASDAQEstrella Immunopharma Inc.
Estrella Immunopharma Inc. share price
ESLA price activity
Last Price
$0.640
Change (24hr)
-0.00 USD (-0.36%)
Volume
28.57K
Volume (4w avg)
-
Open
$0.61
Day Range
$0.61 - $0.69
Previous Close
$0.64
Last Trade
09 Sep, 8:00 pm GMT+0
Delayed
09 Sep, 8:00 pm GMT+0
ESLA price performance
Delayed
09 Sep, 8:00 pm GMT+0
ESLA Market Signals